Association of SCFA in gut microbiome and clinical response in solid cancer patients treated with andi-PD-1 antibody
Open accessThe claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Increased SCFAs point to longer progression-free survival time.
“These results suggest that increased SCFAs point to longer progression-free survival time.40”
In solid cancer patients treated with nivolumab, faecal SCFA abundance was higher in responders than non-responders.
“Nomura et al observed that the abundance of faecal SCFAs in solid cancer patients treated with nivolumab was higher in R than NR.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited by
Sorted by citations
Huang, J., Liu, D., Wang, Y., Liu, L., Li, J., Yuan, J., Jiang, Z., Jiang, Z., Hsiao, W. W., Liu, H., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-321031 · Cited by 539 · see citing works
“40 In this study, we also observed that all the SCFAs including propionate, butyrate, isobutyrate, valerate, isovalerate and hexanoate, increased after treatment with α PD-1 mAb.”
Gut Microbiota and Antitumor Immunity: Potential Mechanisms for Clinical Effect
Baruch, E. N., Wang, J., & Wargo, J. A. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0877 · Cited by 59 · see citing works
“Higher levels of fecal SCFA have been associated with improved clinical response to anti– PD-1 ICB in patients with advanced cancer (28).”
BackgroundHuang, J., Jiang, Z., Wang, Y., Fan, X., Cai, J., Yao, X., Liu, L., Huang, J., He, J., Xie, C., et al. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.06.004 · Cited by 56 · see citing works
Zhang, Y., Liu, X., Wei, Z., Zhang, J., Aiting, W., Wang, J., Lin, Y., Bangwei, C., & Yan, D. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107033 · Cited by 53 · see citing works
Orally Administered Silicon Hydrogen Nanomaterials as Target Therapy to Treat Intestinal Diseases
Wei, K., Gong, F., Wu, J., Tang, W., Liao, F., Han, Z., Pei, Z., Lei, H., Wang, L., Shao, M., et al. (2023) · ACS Nano · doi:10.1021/acsnano.3c06551 · Cited by 44 · see citing works
Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy
Davar, D., & Zarour, H. M. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1129 · Cited by 40 · see citing works
“Across studies, the intake of insoluble dietary fiber (DF), which is not digested but instead fermented into SCFAs by gut bacteria, is associated with increased production of CD103þDCs, enhanced differentiation of activated CD8þT cells into effector cells with memory phenotype (128, 129), and improved outcomes to anti…”
BackgroundThe role of the sex hormone-gut microbiome axis in tumor immunotherapy
Wang, L., Tang, L., Zhai, D., Song, M., Li, W., Xu, S., Jiang, S., Meng, H., Liang, J., Wang, Y., et al. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2185035 · Cited by 31 · see citing works
Bouferraa, Y., Chedid, A., Amhaz, G., Lakkiss, A. E., Mukherji, D., Temraz, S. N., & Shamseddine, A. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158036 · Cited by 18 · see citing works
Reens, A. L., Cabral, D. J., Liang, X., Norton, J. E., Therien, A. G., Hazuda, D. J., & Swaminathan, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643255 · Cited by 13 · see citing works
Recent progress in nanomaterials for bacteria-related tumor therapy
Zhang, F., Wang, S., Yang, S., Ma, F., & Gao, H. (2024) · Biomaterials Science · doi:10.1039/d3bm01952g · Cited by 8 · see citing works
- Authors
- Nomura, M., Nagatomo, R., Inoue, K., Doi, K., Shimizu, J., Baba, K., Saito, T., Matsumoto, S., & Muto, M.
- Affiliations
- Kyoto University (JP)
- Ritsumeikan University (JP)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-10
- Volume
- 30
- Pages
- v509
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2979141921
- Cited by
- 10
- References
- 0
- Citations by year
- 2024: 1 · 2023: 3 · 2022: 1 · 2021: 4 · 2020: 1
- FWCI
- 0.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of Oncology (publishedVersion)
- Funders
- National Natural Science Foundation of China (81802255, 2016YFC0902300)
- Shanghai Shen Kang Hospital Development Center
- Fundamental Research Funds for the Central Universities
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- short-chain fatty acids, gut microbiota, PD-1 inhibitors, immune checkpoint inhibitors, nivolumab, pembrolizumab, solid tumors, melanoma, head and neck cancer, gastrointestinal cancer, genitourinary cancer, treatment response prediction, progression-free survival, fecal metabolites, tumor microenvironment, microbiota metabolites
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
